臨床整形外科45巻10号

2010年10月発行

誌上シンポジウム 骨粗鬆症診断・治療の新展開

骨形成促進薬（PTHなど）の新展開

著者： 酒井昭典¹

所属機関： ¹産業医科大学整形外科

ページ範囲：P.911 - P.916

　わが国の骨粗鬆症治療は現在，骨吸収抑制薬であるビスフォスフォネート製剤とSERM(selective estrogen receptor modulator)が主に用いられている．欧米では骨形成促進薬である副甲状腺ホルモン(parathyroid hormone：PTH)も骨粗鬆症治療薬として使用されている．骨密度増加や骨折抑制に対するPTH単剤の効果と骨吸収抑制薬との併用効果についてのエビデンスが欧米から報告されている．骨形成促進薬はPTH以外に，ラネル酸ストロンチウム，抗スクレロスチン抗体などがあるが，いずれもわが国ではいまだ臨床で使用できる状況ではない．様々な病態を含む骨粗鬆症の治療において，骨形成促進薬の登場は革命的な展開をもたらすことが期待される．

参考文献

1) Black DM, Greenspan SL, Ensrud KE, et al:The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215, 2003

2) Brennan TC, Rybchyn MS, Green W, et al:Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157:1291-1300, 2009

3) Choudhary S, Halbout P, Alander C, et al:Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells:involvement of prostaglandins. J Bone Miner Res 22:1002-1010, 2007

4) Deal C, Omizo M, Schwartz EN, et al:Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis:results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905-1911, 2005

5) Demiralp B, Chen HL, Koh AJ, et al:Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143:4038-4047, 2002

to modulate Wnt activity. J Bone Miner Res 21:1738-1749, 2006

7) Finkelstein JS, Hayes A, Hunzelman JL, et al:The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226, 2003

8) Fujita T, Inoue T, Morii H, et al:Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis:a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296-306, 1999

9) 福永仁夫，小野志磨人，西山剛史：退行期骨粗鬆症患者に対するヒト(1-34)副甲状腺ホルモンの少量連日皮下投与試験．臨床医薬13：3371-3382，1997

10) Greenspan SL, Bone HG, Ettinger MP, et al:Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326-339, 2007

11) Kramer I, Loots GG, Studer A, et al:Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178-189, 2010

12) Li X, Ominsky MS, Niu QT, et al:Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869, 2008

13) Li X, Ominsky MS, Warmington KS, et al:Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588, 2009

14) Li X, Warmington KS, Niu QT, et al:Effects of co-treatment with an anti-sclerostin monoclonal antibody and alendronate in ovariectomized rats. J Bone Miner Res 23 (Suppl 1):S60, 2008

15) Meunier PJ, Roux C, Ortolani S, et al:Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663-1673, 2009

16) Meunier PJ, Roux C, Seeman E, et al:The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468, 2004

17) Neer RM, Arnaud CD, Zanchetta JR, et al:Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001

18) Sakai A, Sakata T, Ikeda S, et al:Intermittent administration of human parathyroid hormone (1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J Bone Miner Res 14:1691-1699, 1999

19) 酒井昭典：骨芽細胞のアポトーシスとPTH．整・災外46：698-699，2003

20) Tanaka S, Sakai A, Tanaka M, et al:Skeletal unloading alleviates the anabolic action of intermittent PTH (1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells. J Bone Miner Res 19:1813-1820, 2004

21) Yamane H, Sakai A, Mori T, et al:The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44:1055-1062, 2009